130250-54-3Relevant articles and documents
SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVILACTIVITY
-
Paragraph 0369; 0373, (2020/11/12)
In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated with AVIL dysregulation using same. In aspects, the disclosed compounds, compositions and methods are useful for treating disorders or diseases in which the regulation, limitation, or inhibition of the expression of AVIL can be clinically useful, such as, for example, the treatment of cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
-
Page/Page column 30; 31, (2018/03/28)
Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
Discovery, synthesis, biological evaluation and structure-based optimization of novel piperidine derivatives as acetylcholine-binding protein ligands
Shen, Jian,Yang, Xi-Cheng,Yu, Ming-Cheng,Xiao, Li,Zhang, Xun-Jie,Sun, Hui-Jiao,Chen, Hao,Pan, Guan-Xin,Yan, Yu-Rong,Wang, Si-Chen,Li, Wei,Zhou, Lu,Xie, Qiong,Yu, Lin-Qian,Wang, Yong-Hui,Shao, Li-Ming
, p. 146 - 155 (2017/01/12)
The homomeric α7 nicotinic receptor (α7 nAChR) is widely expressed in the human brain that could be activated to suppress neuroinflammation, oxidative stress and neuropathic pain. Consequently, a number of α7 nAChR agonists have entered clinical trials as
